Development of a free, easy-to-use electronic patient self-reporting outcomes solution to be deployed through our existing platform ONCOassist and made available globally.
Project Description
We are developing a free, easy-to-use electronic patient self-reporting outcomes solution to be deployed through our existing platform ONCOassist and made available globally.
This will improve the quality of patient care and allow life science companies to gather real-world evidence about how their drugs are performing in the field.
Cutting edge research shows that when cancer patients are systematically surveyed on a regular basis regarding their well being they receive the following benefits:
1. They use the emergency room less.
In one study 34% visited the emergency room compared to 41% receiving usual care.
2. They remain on treatment longer.
An average of 8.2 months compared to 6.3 months.
3. They survive longer.
75% of patients using the surveys were alive after 1 year, compared to 69% of those receiving usual care.
Electronic Patient surveys = Decreased costs and most importantly Improved patient outcomes
Yet despite the improvements in care as a result of these tools, 98% of oncology units globally do not have a system in place for surveying patients on a regular basis.
We are developing a free, easy-to-use electronic patient self-reporting outcomes solution to be deployed through our existing platform ONCOassist and made available globally.
Aim
We will do a phased approach to the development and commercialisation of ONCOpatient:
Phase 1 – Development :
We are currently in the development phase of this project, we are working closely with our partner Dr. Seamus O’Reilly and our clinical lead Dr. Richard Bambury doing requirements gathering. We are also engaging with pharma to get a better understanding of their needs.
Phase 2 – Pilot study:
The next will involve a pilot study and research paper with Dr. Seamus O’Reilly in Cork. This involves a user group of patients using ONCOpatient over an extended period and a before and after comparison.
Phase 3 – English language speaking roll-out:
After this initial phase, we will iterate on the feedback received during the pilot and begin rolling this project out to other parts of the world. We will also begin initial sales to life science companies.
Phase 4 – Global roll-out:
The final phase will involve translation of ONCOpatient and rolling it out globally. This will result in considerably more data being gathered and will include parts of the world that typically wouldn’t see this type of research conducted. Phase 4 is where we will see a large expansion in terms of pharma engagements. We will have robust data sets which can be used for post-market surveillance and reimbursement of products.
Supported by:
